Current News

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Cambridge Cognition Holdings Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £6.4m and Admission to AIM this morning. This is the third AIM IPO in the healthcare sector advised by Walbrook PR in the last four months.

Cambridge Cognition develops and commercialises computerised neuropsychological tests. Cambridge Cognition has two well-established products, CANTABelect™ for use in regulated clinical trials and CANTABeclipse™ designed for use by researchers working in a non-regulated environment, typically in academia.

A third product, CANTABmobile™, was launched in the UK in May 2012, targeted at mainstream primary healthcare markets, in particular to enable the early detection of dementia. The Directors intend to use funds raised in the Placing to grow sales of CANTABmobile™ and continue development of a similar product for secondary healthcare markets.

The Company's Admission document is available on the Company's website: www.cambridgecognition.com

Cambridge Cognition is the third Healthcare IPO on AIM advised by Walbrook in the last four months. Walbrook advised on the AIM IPO of Venn Life Sciences Holdings Plc which listed in December 2012 and on the AIM IPO of Healthcare Investment Opportunities Plc earlier this month.

Paul McManus, Director of Walbrook PR, said: "We are delighted to work with the Cambridge Cognition team, who have an exciting technology that can make a real impact on the 400,000 people in the UK who are undiagnosed with dementia. This is our third Healthcare IPO in the last four months and with the recent addition of Mike and Anna to the Healthcare team demonstrates our strong position in this space."